Urinary tract infections (UTI) are common worldwide and are becoming increasingly difficult to treat because of the development of antibiotic resistance. Immunocompetent murine models of human UTI have been used to study pathogenesis and treatment but not for investigating resistance development after treatment with antibiotics. In this study, intravesical inoculation of uropathogenic Escherichia coli CFT073 in immunocompetent Balb/c mice was used as a model of human UTI. The value of the model in investigating antibiotic exposure on in vivo emergence of antibiotic resistance was examined. Experimentally infected mice were treated with 20 or 200 mg/kg ampicillin, 5 or 50 mg/kg ciprofloxacin, or 100 or 1000 mg/kg of fosfomycin. Ampicillin and ciprofloxacin were given twice daily at 8 h intervals, and fosfomycin was given once daily. Antibiotic treatment began 24 h after bacterial inoculation and ended after 72 h following the initial treatment. Although minimum inhibitory concentrations (MIC) for the experimental strain of E. coli were exceeded at peak concentrations in tissues and consistently in urine, low levels of bacteria persisted in tissues in all experiments. E. coli from bladder tissue, kidney, and urine grew on plates containing 1× MIC of antibiotic, but none grew at 3× MIC. This model is not suitable for studying emergent resistance but might serve to examine bacterial persistence.
The authors proposed a simple, high throughput liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of ciprofloxacin in small sample volumes of plasma, urine, bladder and kidneys of mice. d8-Ciprofloxacin was used as an internal standard (IS) which efficiently tracked the matrix effect in different matrices. The method employed 20 μL of plasma/30 μL of urine or tissue homogenate for sample processing using a simple protein precipitation technique. The processed samples were chromatographed on a C18 column by using a mixture of 5 mM ammonium formate (0.1% formic acid)–acetonitrile as the mobile phase at a flow rate of 0.6 mL min−1 with a gradient elution for 3 min. The calibration curve obtained was linear over the concentration range of 100–5000 ng mL−1 with r2 ≥ 0.99 in all matrices. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. The multiple reaction-monitoring mode (MRM) was used for the quantification of ion transitions at m/z 332.1/230.8 and 340.1/296.1 for the analyte and the IS, respectively. The validated method was used for preclinical studies of antimicrobial resistance in mice.
2 December 2022 in Clinical Pharmacology & Therapeutics